Abstract
Teicoplanin, a new glycopeptide antibiotic, has been used to treat twelve patients with bacterial endocarditis due to Gram-positive organisms. Teicoplanin has activity against Gram-positive bacteria similar to vancomycin but therapeutic levels are maintained by a single daily dose, given as an intravenous bolus. Of six patients with native valve infections, two cases, due to viridans streptococci, were successfully treated with teicoplanin alone and two others, caused by Streptococcus faecalis, were cured by combinations including teicoplanin. One of these patients sustained high tone hearing loss during treatment. The remaining two patients were drug addicts with endocarditis due to Staphylococcus aureus which recurred despite repeated multiple therapy. Of six prosthetic valve infections, antibiotic combinations including teicoplanin cured three cases, caused by streptococci. Infection persisted or treatment was curtailed in three cases of Staphylococcus epidermidis endocarditis. In this small open study, teicoplanin appeared as effective as vancomycin in the treatment of endocarditis but had the considerable advantage of ease of administration.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chambers H. F., Sande M. A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul;26(1):61–64. doi: 10.1128/aac.26.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Farber B. F., Moellering R. C., Jr Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983 Jan;23(1):138–141. doi: 10.1128/aac.23.1.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kucers A. Vancomycin. J Antimicrob Chemother. 1984 Dec;14(6):564–567. [PubMed] [Google Scholar]
- Maher E. R., Hollman A., Grüneberg R. N. Teicoplanin-induced ototoxicity in Down's syndrome. Lancet. 1986 Mar 15;1(8481):613–613. doi: 10.1016/s0140-6736(86)92830-8. [DOI] [PubMed] [Google Scholar]
- Malacoff R. F., Frank E., Andriole V. T. Streptococcal endocarditis (nonenterococcal, non-group A): single vs combination therapy. JAMA. 1979 Apr 27;241(17):1807–1810. [PubMed] [Google Scholar]
- Sullam P. M., Täuber M. G., Hackbarth C. J., Sande M. A. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1985 Jan;27(1):135–136. doi: 10.1128/aac.27.1.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
- Williams A. H., Grüneberg R. N. Teicoplanin. J Antimicrob Chemother. 1984 Nov;14(5):441–445. [PubMed] [Google Scholar]
- Wilson W. R., Giuliani E. R., Danielson G. K., Geraci J. E. Management of complications of infective endocarditis. Mayo Clin Proc. 1982 Mar;57(3):162–170. [PubMed] [Google Scholar]
- Wilson W. R., Jaumin P. M., Danielson G. K., Giuliani E. R., Washington JA I. I., Geraci J. E. Prosthetic valve endocarditis. Ann Intern Med. 1975 Jun;82(6):751–756. doi: 10.7326/0003-4819-82-6-751. [DOI] [PubMed] [Google Scholar]